Rejuvenate Biomed and SAS unveil AI tool to accelerate age-related drug development
The organizations say this collaboration uses the strengths of both to create a cutting-edge platform designed to uncover new insights into drugs, diseases, and biological networks by systematically exploring hidden biological patterns.
The new discovery tool, to be developed on SAS Viya, a robust cloud-native AI and data platform, will, they say, combine Rejuvenate Biomed’s clinically validated AI-driven drug discovery capabilities with SAS’s extensive AI expertise. This collaboration is promising to enhance the efficiency and effectiveness of drug repurposing efforts, particularly for age-related diseases.
“Our partnership with SAS amplifies the core strengths of both our R&D teams,” said Dr Ann Beliën, founder and chief executive officer of Rejuvenate Biomed. “By embracing this partnership and leveraging the capabilities of SAS Viya, we expect to meaningfully de-risk and accelerate the development of our internal portfolio while enhancing our discovery platform and partnering capabilities.”
The low-code tool is designed for ease of use, allowing bioscience researchers with limited coding experience to harness powerful analytics. It will also serve advanced computational biology teams by providing a foundation for developing sophisticated analytics models. The tool will utilize SAS Visual Analytics for creating comprehensive reports, enabling researchers to derive actionable insights from complex biomedical data.
“Our collaboration with Rejuvenate Biomed places us at the forefront of AI in biomedical research, reinforcing our commitment to supporting cutting-edge applied AI and analytics through SAS Viya,” said Udo Sglavo, vice president of Applied AI and Modeling at SAS.
“Rejuvenate Biomed’s endorsement of SAS Viya to further develop their unique and proprietary drug discovery engine is a testament to our commitment to being the premier provider of structured and scalable AI solutions that enhance data analysis efficiency and accelerate the entire drug development life cycle.”
This partnership not only equips Rejuvenate Biomed with the tools to scale its drug discovery platform but also strengthens its capacity to provide third-party services and expand its drug development pipeline. By utilizing AI to uncover non-trivial and novel biological interactions, Rejuvenate Biomed aims to accelerate the identification of potential therapeutic candidates and advance their development.
Rejuvenate Biomed is a clinical-stage biotechnology company focused on developing therapeutics targeting the root causes of age-related diseases. Using its AI-enabled in silico CombinAge and in vivo CelegAge platforms, the company has built a pipeline of unique combination drugs addressing various age-related conditions, including neuromuscular, musculoskeletal, metabolic, cardiovascular, nephrological, and neurodegenerative diseases. Its lead asset, RJx-01, is phase 2-ready and has shown significant potential in treating sarcopenia.
Rejuvenate Biomed said its disease-agnostic drug discovery platforms will continue to generate insights for future therapeutics, driving pipeline growth and fostering potential partnerships. Based in Belgium, Rejuvenate Biomed the company says it is committed to promoting healthy aging and advancing the science of age-related disease treatment.
